Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

Autor(es):Mostrar menos -

Clovis Artur Silva ; Leonard de Vinci Kanda Kupa ^[2] ; Ana Cristina Medeiros-Ribeiro ^[3] ; Sandra Gofinet Pasoto ^[4] ; Carla Gonçalves Schahin Saad ^[5] ; Emily Figueiredo Neves Yuki ^[6] ; Joaquim Ivo Vasques Dantas Landim ^[7] ; Victor Hugo Ferreira e Léda ^[8] ; Luisa Sacchi de Camargo Correia ^[9] ; Artur Fonseca Sartori ^[10] ; Carolina Campagnoli Machado Freire Martins ^[11] ; Carolina Torres Ribeiro ^[12] ; Filipe Waridel ^[13] ; Victor Adriano de Oliveira Martins ^[14] ; Samuel Katsuyuki Shinjo ^[15] ; Danieli Castro Oliveira Andrade ^[16] ; Percival Degrava Sampaio-Barros ^[17] ; Eduardo Ferreira Borba Neto ^[18] ; Nadia Emi Aikawa ; Eloisa Bonfa ^[20]

• Tipo de documento: Artigo Científico
• Fonte: ADVANCES IN RHEUMATOLOGY; v. 63, 2023-09-01.

Resumo

Abstract Background Data on post-acute COVID-19 in autoimmune rheumatic diseases (ARD) are scarce, focusing on a single disease, with variable definitions of this condition and time of vaccination. The aim of this study was to evaluate the frequency and pattern of post-acute COVID-19 in vaccinated patients with ARD using established diagnosis criteria. Methods Retrospective evaluation of a prospective cohort of 108 ARD patients and 32 non-ARD controls, diagnosed with SARS-CoV-2 infection (RT-PCR/antigen test) after the third dose of the CoronaVac vaccine. Post-acute COVID-19 (≥ 4 weeks and > 12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria. Results ARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of ≥ 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p = 0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p = 0.5419). Regarding ≥ 4 weeks post-acute COVID-19, frequencies of ≥ 3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p = 0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p = 0.1322). Further analysis of the risk factors for ≥ 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p > 0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p > 0.05), with fatigue and memory loss being the most frequent manifestations. Conclusion We provide novel data demonstrating that immune/inflammatory ARD disturbances after third dose vaccination do not seem to be a major determinant of post-acute COVID-19 since its pattern is very similar to that of the general population. Clinical Trials platform (NCT04754698). (AU)

• Processo FAPESP: 15/03756-4 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
• Beneficiário: Eloisa Silva Dutra de Oliveira Bonfá
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 22/09566-6 - Imunogenicidade e segurança de doses de reforço da vacina CoronaVac em pacientes com doenças reumatológicas autoimunes
• Beneficiário: Filipe Waridel
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 19/21173-7 - Avaliação do tratamento do lúpus eritematoso cutâneo com talidomida: fatores clínicos, laboratoriais e histológicos associados à resposta clínica e efeitos adversos
• Beneficiário: Carolina Torres Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 21/08455-3 - Imunogenicidade e segurança da vacina Coronavac em pacientes com doenças reumatológicas autoimunes: síndrome de Sjörgren primária
• Beneficiário: Carolina Campagnoli Machado Freire Martins
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 18/09937-9 - Análise do perfil imune da saliva e soro dos pacientes com Síndrome de Sjogren primária
• Beneficiário: Victor Adriano de Oliveira Martins
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 22/09565-0 - Síndrome pós Covid-19 em pacientes com doenças reumatológicas autoimunes
• Beneficiário: Artur Fonseca Sartori
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 19/17272-0 - Avaliação da relevância dos níveis sanguíneos de drogas utilizadas em doenças autoimunes reumatológicas no acompanhamento da segurança, eficácia e aderência à terapêutica
• Beneficiário: Leonard de Vinci Kanda Kupa
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado